Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Lacosamide accepted for use in NHS Scotland

Lacosamide (Vimpat) has been accepted for use in NHS Scotland for thetreatment of epilepsy in patients aged 16 years and over with partialonset seizures, as an add-on to existing therapy, following the latestround of assessments by the Scottish Medicines Consortium. Use oflacosamide is restricted to patients with refractory epilepsy

Lacosamide (Vimpat) has been accepted for use in NHS Scotland for the treatment of epilepsy in patients aged 16 years and over with partial onset seizures, as an add-on to existing therapy, following the latest round of assessments by the Scottish Medicines Consortium. Use of lacosamide is restricted to patients with refractory epilepsy.

Doripinem (Doribax) has been accepted for restricted use as a second- or third-line treatment for adults with complicated intra-abdominal infection that is resistant to current conventional treatments.

Fentanyl buccal tablets (Effentora) and sublingual tablets (Abstral) have been accepted for the treatment of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Use of these drugs should be restricted to patients who are unsuitable for other short-acting opioids.

Also accepted for use are sugammadex (Bridion) and adalimumab (Humira). Sugammadex is accepted for restricted use for the immediate reversal of rocuronium-induced neuromuscular blockade, in adults only.

Adalimumab is accepted for use in combination with methotrexate (or as a monotherapy when methotrexate is inappropriate or not tolerated) for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13–17 years who have an inadequate response to one or more disease-modifying antirheumatic drugs restricted to use within specialist rheumatology services.

Lapatinib (Tyverb), etravirine (Intelence), extended release epidural morphine (Depodur), etonogestrel 11.7mg/ethinylestradiol 2.7mg contraceptive vaginal ring (NuvaRing) and Pemetrexed (Alimta), in combination with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, were not recommended.

Citation: The Pharmaceutical Journal URI: 10049454

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.